FOXO3/TRIM22 axis abated the antitumor effect of gemcitabine in non-small cell lung cancer via autophagy induction

BACKGROUND: Non-small cell lung cancer (NSCLC) accounts for more than 80% of the total lung cancer and gemcitabine (GEM)-based chemotherapy is the first-line therapeutic approach for NSCLC treatment. Owing to acquired chemo-resistance, the prognosis of NSCLC patients receiving GEM treatment is still...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Yang, Liang, Heng-Xing, Zhang, Chun-Min, Zou, Min, Zou, Bi-Bo, Wei, Wei, Hu, Wen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2020
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8798778/
https://www.ncbi.nlm.nih.gov/pubmed/35117439
http://dx.doi.org/10.21037/tcr.2019.12.33

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8798778/
https://www.ncbi.nlm.nih.gov/pubmed/35117439
http://dx.doi.org/10.21037/tcr.2019.12.33

Ejemplares similares